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Abstract
Background: The first influenza pandemic of the 21th century was ignited by a new strain of influenza A virus (A/
H1N1pdm). Specific patient groups, including those with comorbidities, pregnant women, young children, older
and immunocompromised patients, are at increased risk for serious influenza-related disease. This study was aimed
at investigating the influence of clinical presentation, antiviral treatment and possible drug resistance-associated
mutations, on the extent and duration of viral shedding in patients infected with A/H1N1pdm.
Methods: An observational study was performed, based on retrospective review of clinical and laboratory records of
patients who were hospitalized for A/H1N1pdm infection at the National Institute for Infectious Diseases “L.
Spallanzani”, Rome, Italy, between April 24 and December 31, 2009. Among 119 hospitalized patients, 39 were
selected for a post hoc analysis, based on the availability of serial nasopharyngeal swabs samples and related
information.
Results: Eleven out of the 39 study patients (28.2%) presented with pneumonia; 29 (74.4%) received antiviral
treatment. Patients with pneumonia were significantly older than patients without pneumonia. The mean values of
viral RNA concentration were not significantly increased in patients with pneumonia, but a significant increase in the
duration of viral shedding was observed as compared to patients without pneumonia. In patients receiving antivirals,
the viral RNA concentration was significantly reduced in comparison to untreated patients at days 4-5 after symptom
onset, while the overall duration of viral shedding was only marginally affected. A significant correlation between
duration of viral shedding and time elapsed between symptom onset and therapy start was observed, with a
significant reduction of days of viral shedding when therapy was initiated within 2 days of symptoms appearance. No
known drug resistance mutations were detected in patients with prolonged viral shedding.
Conclusions: Our results show that severe respiratory illness is associated with delayed virus clearance in patients
with A/H1N1pdm infection. Antivirals caused an early reduction of viral load, but only marginally affected the
overall duration of shedding. Prolonged shedding was not associated with the emergence of strains carrying
known drug-resistance mutations.
Background
In March/April 2009, a new pandemic influenza A virus
(A/H1N1pdm) emerged in Mexico and spread rapidly
via human-to-human transmission, originating the first
pandemic of the 21th century [1].
A recent overview of the clinical aspects of A/H1N1pdm
infection has been published by WHO [2]. Specific patient
groups, including those with comorbidities, pregnant
women, young children, older patients and individuals
with compromised immunity, are at higher risk than the
general population for serious influenza-related disease
and hospitalization [3].
Prolonged course of illness and severe complications
seem to be associated with a delayed presentation for
care, higher initial viral loads in upper respiratory sam-
ples [4] and emergence of antiviral-resistance [5].
Previous studies have shown that in uncomplicated ill-
ness, A/H1N1pdm titers in nasopharyngeal swabs (NPS)
peak on the day of symptom onset and gradually decline
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any medium, provided the original work is properly cited.thereafter [6], while in severely ill patients higher viral
load and slower decline of viral shedding are observed
[2]. In addition, a more protracted viral replication has
been described in adults hospitalized with seasonal
influenza as compared to outpatients with uncompli-
cated illness [7].
Oseltamivir, one of the neuraminidase inhibitors (NAI),
has been the drug of choice for treatment of A/H1N1pdm
infection; in addition, 2 other drugs were available: zana-
mavir, which is a US Food and Drug Administration-
approved inhaled NAI [8], and peramivir, which is an
intravenous NAI released under an emergency use author-
ization during the pandemic [9]. In case of an uncompli-
cated illness, the early use of oseltamivir is usually
associated with prompt clearance of infectious influenza
A/H1N1pdm virus from the upper respiratory tract [10].
The rapid curtailment of active viral replication in the
respiratory tract, determined by antiviral therapy, may
reduce the duration of hospitalization [11] and the risk of
progression to severe disease [12,13]. Moreover, the pro-
phylactic administration of oseltamivir to subjects exposed
to influenza A/H1N1pdm has been reported to reduce the
rate of symptomatic infection, although it does not always
prevent the infection [14]. In patients treated with oselta-
mivir, younger age (< 13 years) has been associated with
prolonged viral shedding, while clinical severity has been
associated with a higher viral load in the upper respiratory
tract [15].
The aim of present study was to establish the influ-
ence of clinical presentation and of antiviral treatment,
as well as of possible drug resistance-associated muta-
tions, on the extent and duration of viral shedding in
patients infected with influenza A/H1N1pdm. To this
aim we performed an observational study, by retrospec-
tively reviewing the clinical and laboratory records of
patients infected with influenza A/H1N1pdm who were
hospitalized at the “L. Spallanzani” National Institute for
Infectious Diseases in Rome, Italy, between April 24 and
December 31, 2009.
Methods
Patients
During the study period (April 24 - December 31, 2009),
119 patients were hospitalized at the “L. Spallanzani”
National Institute for Infectious Diseases, of whom 54
presented with pneumonia. Hospitalization was not a
general hallmark of clinical severity, as the clinical man-
agement of patients changed during the study period, in
compliance with the modifications in the National policy
of pandemic influenza management. In particular, dur-
ing the pandemic containment response, patients with
laboratory confirmed infection were hospitalized not
only on the basis of clinical severity, but also to isolate
them from the general population and limit the spread
of a new and potentially serious infectious disease. From
August 2009 onwards, patients were hospitalized if they
developed potentially serious medical conditions or if
the exacerbation of their underlying chronic illnesses or
severe symptoms were considered to be unmanageable
at home [16].
For the hospitalized patients, the local hospital policy
for pandemic influenza management included the
assessment of viral shedding at subsequent time points
during the hospitalization period, in order to tailor the
individual isolation measures, and to monitor the effi-
cacy of treatment in patients receiving antivirals.
Clinical and laboratory records of patients presenting
at the hospital for A/H1N1pdm infection, for whom
serial nasopharyngeal swab samples had been collected
during hospitalization, were reviewed.
This study was exempt from ethical review, and no
approval for use of data was necessary, since it was based
on a retrospective chart review and analyses were per-
formed on an anonymized database. To this respect, the
local policy was complying with the international policy
recently reviewed [17], and with the current Italian
legislation.
Specimen collection and laboratory investigation
During the study period, the Virology Laboratory of “L.
Spallanzani” provided diagnostic service for patients
referred by the local admission department and by other
regional hospitals. Nasopharyngeal swabs, placed in viral
transport medium, were sent to the laboratory within 12
hours of collection. Upon arrival in the laboratory, the
samples were divided in two aliquots and stored frozen at
-80°C if not processed immediately.
From all samples, nucleic acids were purified with the
QIAamp Virus BioRobot MDx kit (QIAGEN, Valencia,
CA, USA) on an MDx BioRobot platform. A/H1N1pdm
diagnosis was based on the positivity to the real-time
reverse trascriptase-polymerase chain reaction (RT-PCR)
established by the Centers for Diseases Control and Pre-
vention (CDC), specific for detection and characterization
of A/H1N1pdm virus [18]. Both pan-influenza A (target-
ing M gene), swine influenza A-specific (targeting NP
gene) and A/H1N1pdm-specific (targeting H gene) pri-
mer/probe sets were used; in parallel, the constitutive gene
RNAseP was amplified, as positive control of extraction
and amplification.
For quantitative evaluation, a reference standard curve
was prepared by using a reference influenza A/H1N1pdm
virus preparation supplied by the European Network for
Diagnostics of Imported Viral Diseases (ENIVD), contain-
ing a known genome-equivalent concentration (3.55 × 10
6
genomes/ml). For each sample, the M gene cycle threshold
value was plotted against the calibration curve and the
values expressed as copies/mL of the starting material.
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lished by Probit analysis in our laboratory.
T h ep r e s e n c eo fd r u gr e s i s t a n c em u t a t i o n sw a se s t a b -
lished by sequencing the neuraminidase (NA) gene. Speci-
fically, nucleic acids were amplified by in house methods
using One-Step qRT-PCR system (Invitrogen, Carlsbad
CA, USA) to yield partial (forward: 5’-gacaacagtataa-
gaatcggttc-3’ position 307-329 nt; reverse: 5’-acccacggtc-
gattcgagcc-3’, position 892-911) or full-length sequences
(forward: 5’-atgaatccaaaccaaaagataataacc-3’, position 1-27;
reverse: 5’-gtcaatggtaaatggcaactcagc-3’, position 1380-
1403) of the NA gene. Sequencing was performed on an
automated ABI Prism 3130 instrument (Applied Biosys-
tems, Foster City CA, USA) by using the Big Dye3.1 cycle
sequencing kits provided by the same manufacturer. All
the sequences have been deposited in GenBank with the
following accession numbers [GenBank: CY052089;
CY052076; CY052087; CY055373; CY055390; CY052092;
from CY064903 to CY064921; CY064937 and CY064938].
Statistical evaluation
Influenza viral RNA concentration (expressed in copies/
mL) were Log10 transformed for statistical analysis. For
most variables, descriptive statistics, such as mean ± stan-
dard deviation (SD), median with interquartile range
(IQR), and proportion (%), were calculated. An arbitrary
value of 1.9 Log10 copies/ml was assigned to PCR-nega-
tive samples when comparing the mean values from the
various groups of patients. The student’s t, Mann-Whitney
U, and c
2 (or Fisher’s exact test when applicable) tests
were used for univariate analysis when appropriate. A
two-tailed p-value < 0.05 was considered significant. Statis-
tical analyses were performed using the SPSS software,
version 16.0 (SPSS).
Results
Viral load according to the time lapse between symptom
onset and presentation for diagnosis
During the whole observation period, nasopharyngeal
swab samples from 2,609 patients were analysed by real-
time RT-PCR, to establish an A/H1N1pdm diagnosis;
among them, 870 samples (33.3%) were A/H1N1pdm-
positive. Among 533 patients (20.4%) for whom the time
of symptom onset was available, the mean viral load in the
diagnostic sample was 5.2 ± 1.3 Log10 copies/ml. As
shown in Figure 1, viral load at first presentation corre-
lated negatively with time since symptom onset (r =
-0.203, p < 0.0001); at day 2 and ≥9, the mean viral load
values were highest (5.7 ± 1.2, p < 0.001) and lowest (4.2 ±
1.5, p = 0.020), respectively.
Before August 2009 all patients with influenza like ill-
ness, mostly with mild symptoms, were referred for
laboratory diagnosis, while, from August onwards, a
diagnosis was only required for severely ill patients; we
may therefore assume that the samples collected in the
first period largely represented mild patients, while
those collected later represented more severe cases.
When comparing the mean viral load values observed in
the diagnostic samples collected before or after August
2009, no significant differences were observed (5.37 ±
1.20 vs. 5.23 ± 1.26, respectively, p = 0.220), suggesting
that the severity of clinical presentation did not affect
viral load values at first clinical observation. Subsequent
studies were performed on better characterized patients
to further investigate this point.
Effect of clinical severity and antiviral treatment on the
extent and duration of viral shedding in hospitalized
patients
Among 119 patients hospitalized during the observation
period at the “L. Spallanzani” National Institute for Infec-
tious Diseases, serial respiratory samples were available
for 39 patients, of whom 11 (28.2%) had pneumonia. The
demographic and clinical characteristics of these patients
are shown in Table 1, where patients are grouped accord-
ing to the presence or absence of pneumonia. The vast
majority (9/11) of patients with pneumonia already
showed this complication at presentation. Two patients
developed pneumonia after hospitalization; they were
coinfected with H. influenzae and M. tuberculosis, respec-
tively, and both received early antiviral treatment.
Patients with pneumonia were significantly older than
those without pneumonia (median 51 vs. 26 years, p <
0.001) and more likely to present with dyspnoea (63.6%
v s .2 1 . 4 % ,p=0 . 0 3 5 )b u tl e s sl i k e l yt oh a v ea s t h e n i ao r
malaise (36.4% vs. 85.7%, p = 0.009) and coryza (9.1%

Figure 1 Correlation of initial viral load with the duration after
symptom onset in 533 patients. The analysis was performed on
533 NPS collected during the first visit and sent to the Virology
Laboratory of the National Institute for Infectious Diseases “L.
Spallanzani”, Rome, Italy for laboratory diagnosis (r = -0.203,
p < 0.0001).
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observed among the two groups (Table 1).
In 11 patients with pneumonia, no additional compli-
cations were observed, while, among patients without
pneumonia, 6 of 28 (21.4%) presented one of the follow-
ing complications: exacerbation of chronic obstructive
pulmonary disease (COPD) or of asthma (n = 4, 14.3%);
petechial rush (n = 1, 3.6%); elevated ALT (n = 1, 3.6%).
Twenty-nine out of 39 patients received antiviral treat-
ment with oral oseltamivir, 25 (86.2%) at standard
dosage (i.e. 75 mg twice/day) [19] while 4 (13.8%) at
increased dosage (i.e. 150 mg twice/day), according to
the medical judgment of the treating physician; in the
late phases of hospitalization, intravenous zanamivir
replaced oral oseltamivir in 2 patients with pneumonia,
initially treated with standard (n = 1) or increased
dosage (n = 1) of oseltamivir.
Oseltamivir treatment was initiated on the same day
of symptom onset (day 0) for 1 (3.5%), at day 1 for 8
(27.6%) and at day 2 for 7 (24.1%) patients; for the 13
remaining patients (44.8%) therapy start was in a range
of 3-13 days from symptom onset. Median therapy
duration was 7 days (IQR, 7-16.5 days) and 6 days (IQR,
5-8 days) in patients with and without pneumonia,
respectively (p = 0.011). Ten out of 11 patients with
pneumonia (90.9%) received antiviral treatment.
Mean viral load values at presentation were not signif-
icantly different in patients grouped according to clinical
s e v e r i t y ,i . e .p r e s e n c eo ra b s e n c eo fp n e u m o n i a( 5 . 0 1±
1.66 vs. 5.49 ± 1.35, p = 0.360).
Table 1 Demographic and clinical characteristics of 39 patients hospitalized at INMI
With
pneumonia
Without
pneumonia
p value
a
Patients: n. (%) 11 (28.2) 28 (71.8)
Age in years: median (IQR) 51 (41-63.5) 26 (18.5-35.5) < 0.001
Demographics Age ≥65: n. (%) 2 (18.2) 1 (3.6)
Sex: M/F 4/7 19/9
Asthma 2 (18.2) 3 (10.7)
Immunosuppression
b 3(27.3) 3 (10.7)
Diabetes 3 (27.3) 4 (14.3)
Underlying conditions: n. (%) Obesity 3 (27.3) 1 (3.6)
Chronic respiratory failure 1 (9.1) 3 (10.7)
Pregnancy 0 1 (3.6)
Cardiopathy or hypertension 3 (27.3) 3 (10.7)
Others 2 (18.2) 0
Headache 2 (18.2) 14(50.0)
Asthenia or Malaise 4 (36.4) 24 (85.7) 0.009
Arthromyalgia 5 (45.5) 15 (53.6)
Presenting symptoms: n. (%) Chills 2 (18.2) 4 (14.3)
Conjunctivitis 0 4 (14.3)
Cough 10 (90.9) 21 (75.0)
Sore throat 5 (45.5) 16 (57.1)
Coryza 1 (9.1) 14 (50.0) 0.046
Dyspnea 7 (63.6) 6 (21.4) 0.035
Dehydration 1 (9.1) 6 (21.4)
Gastrointestinal symptoms 4 (36.4) 8 (28.6)
Day of illness at presentation: median (IQR) 2 (1-3) 2.5 (1-4)
Respiratory virus coinfections: n. (%) 03
c (10.7)
Antiviral 10 (90.9) 19 (67.9)
Days of therapy: median (IQR) 7 (7-16.5) 6 (5-8) 0.011
Therapy: n. (%)
d Patient starting therapy within 48 h 5 (45.5) 11 (39.3)
Antibiotic/antimycotic 10 (90.9) 11 (39.3) 0.004
Steroid 2 (18.2) 2 (7.1)
a p values ≥0.05 have been omitted.
b HIV, n = 5; hairy cells leukaemia, n = 1.
c Human respiratory syncytial virus type A, n = 2; human rhinovirus, n = 1.
d Unless otherwise specified.
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Page 4 of 10The time course of viral load in these patients was
further analysed with respect to time from symptom
onset, according to presence of pneumonia and adminis-
tration of antivirals. Three or more respiratory speci-
mens for each patient were analysed (164 available
results from a total of 175 collected NPS), sampled over
am e d i a nt i m el a p s eo f7d a y s( I Q R ,4 - 1 4d a y s )a n d5
days (IQR, 3-7 days) since symptom onset for patients
with and without pneumonia, respectively (p = 0.003).
As shown in Figure 2A, the time course of viral load in
NPS from patients with and without pneumonia was
similar. Consistently, the overall mean viral load values
were not significantly different in the 2 groups (3.7 ± 1.5
vs. 3.8 ± 1.7 Log10 copies/mL, respectively). However,
when considering the duration of viral shedding, virus
RNA was detectable for longer time in the NPS from
patients with pneumonia as compared to patients with-
out pneumonia (mean number of days with PCR-positive
NPS since the symptom onset: 15.4 ± 9.0 vs. 7.5 ± 3.4,
p = 0.002; mean number of days with PCR-positive NPS
since the first visit:12.1 ± 7.9 vs. 4.8 ± 3.8 days, p =
0.003). Consistently, from day 6 onward, the proportion
of patients with PCR-positive NPS was significantly
higher in patients with pneumonia as compared to those
without pneumonia. In fact, as shown in Figure 2B, at
days 6-7, 8-9 and ≥10 the proportion of PCR-positive
patients was 100%, 100% and 67.3% for patients with
pneumonia, and 51.2%, 25% and 22.2% for patients with-
out pneumonia, p < 0.001. On the whole, 100% of
patients with pneumonia and 66.7% of patients without
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Figure 2 Time course of viral load and duration of viral shedding according to presence of pneumonia and antiviral treatment. Panels
A and C: mean values and standard deviation (represented by bars) of influenza A/H1N1pdm in NPS at various time points after symptom
onset; panels B and D: proportion of samples positive to influenza A/H1N1pdm PCR according to time from symptom onset. Panels A and B:
patients with pneumonia vs. without pneumonia; Panels C and D: treated vs. untreated patients. In panel A the number of samples collected at
days 0-1, 2-3, 4-5, 6-7, 8-9 and ≥10 were (for patients with pneumonia) 3, 8, 8, 9, 5, and 21 and (for patients without pneumonia) 8, 21, 30, 7, 14
and 10. In panel C the number of samples collected at days 0-1, 2-3, 4-5, 6-7, 8-9 and ≥10 were (for treated patients) 9, 24, 24, 23, 13 and 29,
and (for untreated patients) 2, 5, 14, 13, 6 and 2. * p ≤ 0.010, ** p ≤ 0.010, *** p ≤ 0.010; §: p = 0.002.
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Page 5 of 10pneumonia had PCR-positive samples after day 6 from
start of symptoms, approaching statistical significance
(p = 0.063). To be noted, one patient with pneumonia,
despite oseltamivir and zanamivir treatment, had PCR-
positive NPS until day 34 post symptom onset.
Analysis of viral load and duration of shedding was per-
formed also according to antiviral therapy. When consid-
ering the overall mean values of viral load, these were
significantly lower in treated compared with untreated
patients (3.6 ± 1.6 vs. 4.2 ± 1.7 Log10 copies/mL, p =
0.038). In Figure 2C the time course of viral loads in
patients grouped in treated vs. untreated is shown. In
untreated patients, the viral load steadily increased from
baseline up to days 4-5 after symptom onset, then
declined. At days 4-5 the mean viral load value in
untreated patients was significantly higher than that of
treated patients (5.4 ± 1.2 vs. 3.9 ± 1.5 Log10 copies/mL,
respectively; p = 0.002). When considering the length of
viral shedding in untreated vs. treated patients, there was
a tendency to shorter duration in the treated group,
although the difference was not statistically significant
(7.7 ± 1.8 vs. 10.2 ± 7.2 days, p = 0.378, Figure 2D).
Among treated patients, a positive correlation was
observed between the overall duration of viral shedding
and the days elapsed between symptom onset and start
of antiviral therapy (Figure 3, r = 0.531, p = 0.016). Con-
sistently, the mean duration of shedding in patients who
started treatment within 2 days of therapy initiation was
significantly shorter than in those who started therapy at
later times (6.6 ± 2.7 vs. 13 ± 8.5, p = 0.042, respectively).
Table 2 reports the analysis of the association of a num-
ber of factors with the prolonged shedding (positivity
of NPS samples to influenza PCR for > 6 days) of A/
H1N1pdm. As can be seen, among the considered factors,
presence of any complication (pneumonia, exacerbation of
COPD or asthma, petechial rash, elevated ALT), pneumo-
nia and duration of antiviral administration, but not
administration per se, were significantly associated with
prolonged viral shedding. These data support that the
deciding factor for prolonged shedding was, in fact, the
presence of pneumonia; however, due to the small number
of cases, it was not possible to apply a multivariate analysis
to specifically address this point.
Analysis of antiviral resistance
Since the emergence of resistance-associated mutations is
among the factors associated with prolonged viral shed-
ding, particularly in patients treated with antivirals [20],
we decided to establish the mutational pattern for those
patients for whom sufficient sample volume was available
to perform the sequence analysis. In particular, NA
sequencing analysis of pandemic influenza virus was
achieved for 13 treated patients (8/13 with shedding
duration > 6 days, of whom 3 were immunocompro-
mised, 2 with HIV and 1 with leukaemia; 12 with oselta-
mivir alone, 1 sequentially treated with oseltamivir and
zanamivir). The total number of analysed NPS from 13
treated patients was 16, with a median sampling time of
2.88 (range 0-15) days from therapy onset. For compari-
son, 5 untreated patients (4 with shedding duration > 6
days) were also analysed. No mutations known to be
associated with NAI resistance were detected.
Discussion
In this study, the concentration of influenza A/
H1N1pdm RNA in NPS was evaluated in relation to the
time from start of symptoms, considering all patients
with confirmed infection whose samples had been sent
for diagnosis to the Virology Laboratory of “L. Spallan-
zani” Institute.
In addition, the influence of clinical severity and of anti-
viral treatment on the extent and duration of viral shed-
ding was evaluated in a group of hospitalized patients, for
whom sequential NPS samples had been analysed. The
clinical findings of these patients were not uniformly
severe, since, at least at the beginning of pandemics, most
patients with confirmed infection were hospitalized.
Concerning the first point, the data shown in Figure 1,
representing a cross-sectional evaluation of the viral
load of patients at first presentation, indicate that the
highest initial values of H1N1/pdm RNA concentration
were observed in patients presenting for influenza diag-
nosis on day 2 from start of symptoms. A significant
trend to decrease according to the distance between the
symptom onset and first sampling was observed, in line
with the reports from other groups [6,21].
Concerning the second point, in patients serially
sampled during their hospitalization period, a progressive
decline of viral load was observed in those who received
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Figure 3 Correlation of duration of viral shedding with interval
between symptom onset and therapy start. The analysis was
performed on data from 20 patients treated with inhibitors of NA,
who reached undetectable PCR during the observation period (r =
0.531, p = 0.016).
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Page 6 of 10antivirals, while in untreated patients an increase of viral
load was observed during the first 5 days, followed by a
decrease (Figure 2C). This result is in apparent contrast
with the trend to a progressive decline of viral load at
first presentation shown in Figure 1. However, the data
from this figure represent a cross-sectional analysis of
first viral loads detected in patients at diagnosis, and
therefore are not directly comparable to those from Fig-
ure 2, where the time course in patients serially sampled
is reported.
In apparent contrast with data from other authors
[15], in the present study mean viral load values at
Table 2 Positivity of nasopharyngeal swabs for influenza virus RNA 6 days after symptom onset according to patient
characteristics
Variable N. of patients positive for
viral RNA 6 days after
symptom onset/total (%)
p value
a
Sex
Male 15/21 (71.4)
Female 13/16 (81.3)
Immunosuppression
b
Present 6/6 (100)
Absent 22/31 (71)
Underlying lung disease
c
Present 7/8 (87.5)
Absent 21/29 (72.4)
Any complication
d 0.005
Present 17/17 (100)
Absent 11/22 (50)
Any complication excluding pneumonia
Present 6/6 (100)
Absent 11/20 (55)
Pneumonia 0.02
Present 11/11 (100)
Absent 17/26 (65.4)
Antiviral treatment
Yes 21/28 (75)
No 7/9 (77.8)
Time from symptom onset to initiation of treatment
≤ 2 days 10/15 (66.7)
> 2 days 11/13 (84.6)
Antiviral treatment regimen
e
standard 4/5 (80)
intensified 17/23 (73.9)
Antiviral treatment duration 0.02
≤ 5 days 3/8 (37.5)
> 5 days 18/20 (90)
Antibiotic/antimycotic treatment
yes 18/20 (90)
no 10/17 (58.8)
Steroid treatment
yes 4/4 (100)
no 24/33 (72.7)
a by chi-square test; p values ≥0.05 have been omitted.
b HIV or hairy cells leukaemia.
c COPD or Asthma.
d Pneumonia, exacerbation of COPD or asthma, petechial rash, elevated ALT.
e Standard treatment: oseltamivir 75 mg twice/day; intensified treatment: increased dosage of oseltamivir or oseltamivir+zanamivir.
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grouped according to clinical severity, i.e. presence or
absence of pneumonia. However, and more importantly,
patients with pneumonia showed a delayed viral clear-
ance. In fact, about 85% of patients without pneumonia
had influenza-negative samples at days 8-9 after symp-
tom onset (Figure 2B), and 78% after this time point,
while a significantly lower proportion of patients with
pneumonia were negative at the same time points. It is
not possible from our results to determine whether the
viral genomes detected in the upper respiratory tract of
patients after the initial stages of the infection corre-
spond to actually infectious virions. Lower positive rates
for virus culture, compared with RT-PCR assay are
commonly observed [4], and other studies have reported
that infectious virus may be detected after the resolution
of fever and sometimes after the completion of therapy
[22].
Although there is the possibility of selection bias, due
to the fact that patients with more severe clinical
courses received protracted care, and were sampled for
longer periods compared to those with milder symp-
toms, these findings are in agreement with a number of
previous reports. For instance, To et al. [21], have
shown a slower decline in viral shedding in patients
with severe conditions as compared to the mild disease
groups, and, recently, Li et al. [15], have shown similar
findings considering treated patients only.
All the factors significantly associated with prolonged
viral shedding, i.e. presence of any complication, pneu-
monia and duration of antiviral administration (Table 2),
are strictly interconnected, suggesting that the deciding
factor for prolonged shedding is, in fact, the presence of
pneumonia. However, because of limited number of
cases, it was not possible to apply multivariate analysis to
identify the effect of one of the variables (pneumonia and
early antiviral treatment) adjusting for the other.
It is reasonable to assume that the delayed clearance
observed in severe cases could be secondary to a worse
control of viral replication, due to a less effective innate
and adaptive immune response, as recently suggested by
our group [23].
Another possible reason for the prolonged virus repli-
cation in the upper respiratory tract may be the emer-
gence of viral strains with reduced susceptibility to NAI.
In fact, resistant strains have been observed after pro-
longed administration of antivirals. These resistant
strains typically contain a single H275Y substitution in
the viral NA gene, and are mostly detected in specimens
obtained from patients with a severely compromised
immune system and from patients who received oselta-
mivir, but still had persistent viral replication [5,20].
The emergence of drug-resistant pandemic influenza
strains is not a major public health concern so far, as
the majority of the influenza A H1N1/pdm viruses are
oseltamivir-susceptible, while oseltamivir-resistant
strains remain infrequent and are still sensitive to zana-
mivir [24]. However, resistant strains have been also iso-
lated in untreated patients, including known or
suspected cases of person to person transmission [25].
In our study, the emergence of resistant strains as a pos-
sible factor underlying the prolonged viral shedding may
be considered negligible, as no mutations known to be
associated to either oseltamivir or zanamivir resistance
were detected in either treated or untreated patients.
To this respect, our findings are in line with recent
observations by other authors. For instance Fleury et al.
reported prolonged influenza A/H1N1pdm shedding not
associated with the emergence of resistance mutation in
the viral NA gene in 2 severely ill patients [26].
The absence of a link between the emergence of resis-
tant strains due to therapy administration and the pro-
longed viral shedding from the upper respiratory tract of
hospitalized patients is further supported by the absence
of statistically significant differences in the persistence of
PCR positivity in treated vs. untreated patients (Figure
2D), despite a significant reduction of viral load observed
at days 4-5 from symptom onset in treated patients (Figure
2C). The lack of significant differences in the persistence
of PCR positivity in treated vs. untreated patients is in
agreement with data from other studies carried out on
seasonal influenza strains [27], and in apparent contrast
with other studies, showing a significant shortening of the
duration of viral shedding in A/H1N1pdm -patients
exposed to NAI [28,10]. In another study conducted only
in treated patients, more prolonged viral shedding was
observed in subjects < 13 years of age than in older
patients [15]. In our study we did not evaluate the associa-
tion between age and delayed virus clearance, since the
age of our patients was rather homogeneous, and our case
series did not include young patients (Table 2), because
our Institute is not a pediatric referral hospital.
Our data indicate a positive correlation between the
overall duration of viral shedding and days elapsed
between symptom onset and start of antiviral therapy
(Figure 3). These results are in agreement with the widely
held concept that early initiation of antiviral therapy is
important in order to obtain an effective control of the
viral replication, and in turn, to shorten the duration of
symptoms [10].
Our study has some limitations: first, the number of
patients is rather small, and the lack of significance of
some differences may be due to insufficient size of the
compared groups; due to the limited number of patients,
it was not possible to apply multivariate analysis to the
factors associated with prolonged shedding; furthermore,
the collection of samples was not prospectively planned,
so the sampling was not conducted at fixed time points.
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upper respiratory tract is shorter and not always repre-
sentative of lower airway shedding [2,26]. In the cases
under study, serial bronchoalveolar lavage (BAL) samples
were analysed only for the patient with leukaemia, who
showed severe pneumonia and received enhanced anti-
viral treatment. In this patient the BAL returned negative
earlier than NPS (day 21 vs. day 34), but no conclusion
can be drawn from this anecdotal observation.
Conclusions
In conclusion, our data indicate that in patients with
influenza A/H1N1pdm infection, severe clinical presen-
tations such as pneumonia are significantly associated
with a prolonged virus shedding. In addition, the admin-
istration of antivirals significantly reduced viral load at
early times from the start of treatment, but only had a
marginal effect on the duration of viral shedding. The
positive correlation between the overall duration of viral
shedding and days elapsed between symptom onset and
start of antiviral therapy underscores the necessity of a
timely initiation of antiviral therapy to obtain an effec-
tive control of viral spread.
Further investigation is mandatory to better under-
stand the significance of prolonged shedding that seems
to occur in patients with severe presentation. No link
between the emergence of resistant strains due to ther-
apy administration and prolonged viral shedding from
the upper respiratory tract of hospitalized patients was
observed in this study. The delayed virus clearance
observed in severe patients is consistent with impaired
innate immunity, as was observed in a recent study by
our group [23]. This may be relevant for the duration of
contagiousness, and may have clinical/pathogenetic
significance.
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